Myelodysplastic syndrome

References

Key articles

Swerdlow SH, Campo E, Harris NL, et al, ed. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006 Jan;81(1):104-30. Abstract

Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct;6(9):902-26. Abstract

Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009:645-55.Full text  Abstract

Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan;4(1):58-77. Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes [internet publication].Full text

Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother. 2008 Jul;9(10):1667-78. Abstract

Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul 15;104(2):579-85. Abstract

Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008 Jul;87(7):527-36. Abstract

Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007 Oct;12(10):1264-73.Full text  Abstract

Reference articles

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.Full text  Abstract

2. Swerdlow SH, Campo E, Harris NL, et al, ed. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

3. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005 Aug 15;104(4):788-93. Abstract

4. Pomeroy C, Oken MM, Rydell RE, et al. Infection in the myelodysplastic syndromes. Am J Med. 1991 Mar;90(3):338-44. Abstract

5. Enright H, Jacobs HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995 Oct;91(2):403-8. Abstract

6. Finelli CC. The myelodysplastic syndromes: Diagnosis, prognosis and therapy. Ital J Med. 2011;5:90-7.

7. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992 Oct;82(2):358-67. Abstract

8. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10(suppl 1):258-69. Abstract

9. Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005 May;19(5):767-75.Full text  Abstract

10. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006 Jan;81(1):104-30. Abstract

11. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10(Suppl 1):258-269. Abstract

12. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998 Jan;83(1):71-86. Abstract

13. West RR, Stafford DA, Farrow A, et al. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res. 1995 Feb;19(2):127-39. Abstract

14. Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct;6(9):902-26. Abstract

15. Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009:645-55.Full text  Abstract

16. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999 May 27;340(21):1649-60.Full text  Abstract

17. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009 Feb;94(2):264-8.Full text  Abstract

18. Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome: acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002 Feb 1;99(3):822-4.Full text  Abstract

19. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-65.Full text  Abstract

20. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007 Aug 10;25(23):3503-10.Full text  Abstract

21. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan;4(1):58-77. Abstract

22. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Sep 26;8(43):73483-500.Full text  Abstract

23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes [internet publication].Full text

24. Fenaux P, Haase D, Sanz GF, et al; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(suppl 3):iii57-69.Full text  Abstract

25. Nordic MDS Group. Guidelines for the diagnosis and treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Ninth update. November 2019 [internet publication].Full text

26. Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother. 2008 Jul;9(10):1667-78. Abstract

27. Fey MF, Buske C, ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi138-43.Full text  Abstract

28. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul 15;104(2):579-85. Abstract

29. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009 Feb;15(2):137-72. Abstract

30. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008 Jul;87(7):527-36. Abstract

31. Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007 Oct;12(10):1264-73.Full text  Abstract

32. Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010 Dec;34(12):1576-88. Abstract

33. Miller W, Holden J, George E, et al. NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia. Lancet Oncol. 2011 Apr;12(4):326-7. Abstract

34. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome: a systematic review and meta-analysis. Haematologica. 2010 Feb;95(2):303-10.Full text  Abstract

35. Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011 May 20;29(15):1987-96. Abstract

36. Sekeres MA. Lenalidomide in MDS: 4th time's a charm. Blood. 2011 Oct 6;118(14):3757-8. Abstract

37. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011 Oct 6;118(14):3765-76. Abstract

38. Leitch HA, Buckstein R, Shamy A, et al. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Crit Rev Oncol Hematol. 2013 Feb;85(2):162-92.Full text  Abstract

39. National Institute for Health and Care Excellence. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. March 2011 [internet publication].Full text

40. Stasi R, Amadori S, Newland AC, et al. Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma. 2005 Apr;46(4):509-16. Abstract

41. Scott BL, Ramakrishnan A, Fosdal M, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010 Jun;149(5):706-10.Full text  Abstract

42. Sekeres MA. Arsenic trioxide as a treatment for myelodysplastic syndrome. Curr Hematol Malig Rep. 2006 Mar;1(1):34-8. Abstract

43. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008 Oct;(suppl 15):40-9.Full text  Abstract

44. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010 Oct 28;116(17):3163-70..Full text  Abstract

45. Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014 Jun 15;120(12):1838-46.Full text  Abstract

46. Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr;7(4):e309-19.Full text  Abstract

47. Foran JM, DiNardo CD, Watts JM, et al. Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: updated enrollment of a phase 1 dose escalation and expansion study. Blood. 2019 Nov 13;134 (Suppl 1): 4254.Full text

48. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020 Jan 9;382(2):140-51.Full text  Abstract

49. Steensma DP, Platzbecker U, Van Eygen K, et al. Imetelstat treatment leads to durable transfusion independence (TI) in RBC transfusion-dependent (TD), non-del(5q) lower risk MDS relapsed/refractory to erythropoiesis-stimulating agent (ESA) who are lenalidomide (LEN) and HMA naive. Blood 2018;132(suppl 1):463.Full text  Abstract

50. Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 Aug 6;136(6):674-83.Full text  Abstract

51. National Institute for Health and Care Excellence. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. March 2011 [internet publication].Full text

52. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88. [Erratum in: Blood. 1998;91:1100.]Full text  Abstract

53. Haider M, Duncavage EJ, Afaneh KF, et al. New insight into the biology, risk stratification, and targeted treatment of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book. 2017;37:480-94.Full text  Abstract

54. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996 Aug;94(2):288-99. Abstract

55. Galanello R, Campus S, Origa R, et al. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):123-34. Abstract

56. Leitch HA, Buckstein R, Zhu N, et al. Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018 Nov;74:21-41.Full text  Abstract

57. Toma A, Fenaux P, Dreyfus F, et al. Infections in myelodysplastic syndromes. Haematologica. 2012 Oct;97(10):1459-70.Full text  Abstract

58. Radsak M, Platzbecker U, Schmidt CS, et al. Infectious complications in patients with myelodysplastic syndromes: a review of the literature with emphasis on patients treated with 5-azacitidine. Eur J Haematol. 2017 Aug;99(2):112-8.Full text  Abstract

59. Mikulska M, Cesaro S, de Lavallade H, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019 Jun;19(6):e188-e199.Full text  Abstract

Use of this content is subject to our disclaimer